Comparison of acellular pertussis-diphtheria-tetanus toxoids and Haemophilus influenzae type b vaccines administered separately vs. combined in younger vs. older toddlers

Pediatric Infectious Disease Journal

Volumn 17, Issue 2, 1998, Pages 164-166

  Rennels, Margaret B ^a,e   Hohenboken, Matthew J ^b   Reisinger, Keith S ^c   Clements, Dennis A ^d   Walter Jr , Emmanuel B ^d   Blatter, Mark M ^c   Nonenmacher, Jean ^b   Hackell, Jill G ^b  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b PFIZER INC   (United States)

^c NIOSH Pittsburgh Research Laboratory   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e University Hospital Bern   (United States)

Author keywords

Combined; Haemophilus influenzae type b; Pertussis; Vaccines

Indexed keywords

BACTERIAL POLYSACCHARIDE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G; PERTUSSIS TOXIN; POLYRIBOSYLRIBITOL PHOSPHATE; TETANUS TOXOID; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS HEMAGGLUTININ;

ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG MIXTURE; FEVER; FIMBRIA; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SKIN MANIFESTATION;

ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; SEROLOGIC TESTS; VACCINES, COMBINED;

EID: 0031906604     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199802000-00019     Document Type: Article

References (7)

1. American Academy of Pediatrics, Committee on Infectious Diseases. Acellular pertussis vaccine: recommendations for use as the initial series in infants and children. Pediatrics 1997;99:282-8.
2. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. MMWR 1997;46:1-25.
3. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention. FDA approval of a Haemophilus b conjugate vaccine combined by reconstitution with an acellular pertussis vaccine. MMWR 1996;45:993-5.
4. Eskola J, Ölander RM, Hovi, T, Litmanen L, Peltola S, Käyhty, H. Randomized trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996;348:1688-91.
5. Pichichero ME, Latiolais T, Bernstein DI, et al. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type B-tetanus toxoid vaccine in two, four- and six month-old infants. Pediatr Infect Dis J 1997;16: 863-70.
6. Madore DV, Anderson P, Baxter BD, et al. Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-liked immunosorbent assay. Clin Diagn Lab Immunol 1996;3:84-8.
7. Pichichero ME, Deloria MA, Rennels MB, et al. A comparison of 12 acellular pertussis vaccines and one whole cell pertussis vaccine given as a fourth dose in 15 to 20 month-old children. Pediatrics 1997;100:772-88.